Does Nirmatrelvir/Ritonavir Influence the Immune Response Against SARS-CoV-2 Independently From Rebound?

    October 2023 in “ Microorganisms
    Filomena Panza, Fabio Fiorino, Gabiria Pastore, Lia Fiaschi, Mario Tumbarello, Donata Medaglini, Annalisa Ciabattini, Francesca Montagnani, Massimiliano Fabbiani
    Image
    Studysummary This study reported that COVID-19 patients treated with nirmatrelvir/ritonavir had lower anti-spike IgG levels and different cytokine patterns compared to those not receiving antiviral treatment, suggesting early antiviral use may alter immune response by reducing viral load and antigen presentation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →